28,770 DexCom, Inc. $DXCM Shares Acquired by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 82,170 shares of the medical device company’s stock after purchasing an additional 28,770 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in DexCom were worth $7,090,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of DXCM. Plato Investment Management Ltd bought a new position in shares of DexCom during the 2nd quarter worth approximately $782,000. Aurora Investment Counsel bought a new position in DexCom during the second quarter worth $2,340,000. E Fund Management Co. Ltd. acquired a new position in shares of DexCom in the second quarter valued at $1,273,000. Silvant Capital Management LLC acquired a new position in shares of DexCom in the second quarter valued at $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of DexCom in the second quarter valued at $89,940,000. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

Shares of DXCM stock opened at $82.29 on Monday. The company has a current ratio of 1.74, a quick ratio of 1.40 and a debt-to-equity ratio of 0.49. The stock has a market cap of $30.69 billion, a P/E ratio of 32.27, a price-to-earnings-growth ratio of 1.37 and a beta of 1.45. The stock has a 50 day simple moving average of $85.82 and a 200 day simple moving average of $74.65. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the business posted $0.61 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, research analysts predict that DexCom, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 3,638 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares in the company, valued at approximately $12,226,367.56. The trade was a 2.42% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the transaction, the director directly owned 29,293 shares of the company’s stock, valued at $2,461,783.72. This trade represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 22,822 shares of company stock valued at $1,920,193 in the last 90 days. 0.28% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Robert W. Baird set a $105.00 target price on shares of DexCom in a research note on Friday, July 31st. Barclays boosted their price objective on DexCom from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday. BTIG Research upped their target price on DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Benchmark upped their price objective on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a report on Friday, July 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $105.00 target price (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $92.91.

Key Stories Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.